Fig. 3: Inhibition of AKT and MEK decreases the expression of FOXM1 and DKK1.

A S2-CP8 cells were treated with AKT inhibitor VIII (5 μM), PD032590 (5 μM), or both inhibitors for 48 h; and TE-5 cells were treated with AKT inhibitor VIII (50 μM), PD032590 (10 μM), or both inhibitors for 48 h. Lysates were probed with the indicated antibodies. Clathrin was used as a loading control. B The mRNA levels of FOXM1 (top panels) and DKK1 (bottom panels) in the S2-CP8 cells and TE-5 cells used in Fig. 3A were measured by quantitative RT-PCR and normalized to UBC. The results are shown as fold-changes compared to the control cells and are expressed as means ± SD from three independent experiments. C Lysates from control S2-CP8 cells, S2-CP8/CKAP4 KO cells, and S2-CP8/CKAP4 KO/CKAP4-HA cells treated with or without PD0325901 (5 μM) for 48 h were probed with the indicated antibodies. Clathrin was used as a loading control. D The mRNA levels of FOXM1 and DKK1 in the S2-CP8 cells used in Fig. 3C were measured by quantitative RT-PCR and normalized to GAPDH. The results are shown as fold-changes compared to the control S2-CP8 cells and are expressed as means ± SD from three independent experiments. *P < 0.05; **P < 0.01 (Student’s t test).